congrat$$$$ ACIU

What a day $$$$$$

I’m surprise ACIU is not trading up 200% today

WOOHOOOOOO WOOHOOOOOO awesome break out

WOOHOOOOOO WOOHOOOOOO

FDA fast track

ACIU$

ACIOU AND SOMETIMES Y

https://finviz.com/quote.ashx?t=ACIU&ty=c&ta=1&p=d

ACIU @$2.15, huge collaboration with Eli Lilly & Genentech!

ROBUST PIPELINE Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases

"Based on our SupraAntigen® and Morphomer® technology platforms, we are advancing one of the industry’s broadest and most diverse clinical-stage pipelines focused on neurodegenerative diseases.
We design first- and best-in-class therapeutic and diagnostic candidates to tackle established and novel disease targets enabling AC Immune’s comprehensive precision medicine approach."

That`s huge! SAP founder is major shareholder with 21% stake!

AC Immune Key Shareholders

About Dietmar Hopp

About Dietmar Hopps dievini Hopp BioTech holding

CEO Andrea Pfeifer about Alzheimer & Parkinson:
(from an interview with german weekly magazine "Die Bunte", may 2022 - through google translator)
We've finally made a breakthrough in Parkinson's

Q: How is the brain destroyed in Alzheimer's and Parkinson's?

A: All neurodegenerative diseases - whether Alzheimer's, Parkinson, ALS – have one thing in common: a different protein that previously has a normal function in the body,
begins for reasons we don't even know yet, to change its structure. It becomes pathological, forms clumps and kills the nerve cells in the brain.
We want to fight these proteins. But that is great for two reasons difficult: The therapies first have to go all the way to be brought to the brain. And then they are only allowed to attack the sick protein, not the healthy one.

Q: Where do you stand in Parkinson's research?

A: We've had a groundbreaking breakthrough this year.
We have developed an imaging method that early diagnosis of Parkinson's disease could. What has been known about Alzheimer's for 20 years was for Parkinson's not yet possible. We can now to the first take a look inside the brains of Parkinson's patients and make the pathological deposits visible. That is a incredibly important first step in diagnosis and treatment development of Parkinson's disease. It's a revolution from my point of view.

Q: Why?

A: This is the only way we can make early and precise diagnoses.
When the first symptoms of Alzheimer's appear, that's it destroys up to 70 percent of nerve cells. It already exists today a blood test with a probability of more than 90 percent ability to predict whether one will fall ill. I am convinced that at some point this will also be possible with Parkinson's will be. And I also firmly believe that against both Diseases it will eventually have vaccinations.

looking good

ACIU clinical stage programs
ACI-7104 and ACI-12589
Their ACI-7104 and ACI-12589 is on alpha-synuclein for Parkinsons desease

Novel targets programs:
Anti-a-syn antibody and Morphomer® a-syn aggregation inhibitor on alpha-synuclein for Parkinsons desease
$$$

Latest ACIU news:
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

ACIU had the most number of Alpha Synuclein drugs under development in 2022!!!
Parkinsons desease gamechanger on todays MJFF breakthrough news!!!!!

Parkinson Breakthrough News for ACIU
MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

alpha-synuclein is key protein here - A number of companies are involved in the development of Alpha Synuclein drugs. One of this few is AC Immune SA (ACIU) -
AC Immune SA had the most number of Alpha Synuclein drugs under development in 2022!!!
Read here about Alpha Synuclein Pipeline Drugs Market

AC Immune SA (ACIU) is currently a Nasdaq-listed 181m company! This one should rocket now!

This one running in sympathy to BIIB news from last night

Went back to single territory within 1.5 hours of trading.

Back to singles today or tomorrow imho over $110,000,000 million NEGATIVE cash flow

$0.03 revenue per share with huge negative operating margins and returns

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -3,592.01%

Management Effectiveness
Return on Assets (ttm) -19.15%
Return on Equity (ttm) -33.76%

Income Statement
Revenue (ttm) 2.07M
Revenue Per Share (ttm) 0.03
Gross Profit (ttm) -44.06M
EBITDA -72.49M
Net Income Avi to Common (ttm) -74.3M
Diluted EPS (ttm) -1.12

Cash Flow Statement
Operating Cash Flow (ttm) -68.32M
Levered Free Cash Flow (ttm) -42.91M

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease

ACI-35.030 was safe and well tolerated with no safety concerns observed. Results support plans to further develop the Alzheimer’s vaccine into Phase 2/3

LAUSANNE, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. No clinically relevant adverse events were observed. AC Immune and strategic partner Janssen Pharmaceuticals, Inc., believe these interim findings from the first two dosing groups support plans to advance the development of ACI-35.030 for the treatment of AD.

Immunization with anti-Tau vaccines represents a novel strategy for the treatment of AD and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030 is a first-in-class vaccine candidate designed to generate a specific antibody response against pTau proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology, which is a major hallmark of AD.

These new results provide encouraging clinical support for ACI-35.030, which employs a new vaccine formulation to achieve active immunization that significantly improves antibody responses in older patients with potentially attenuated immune systems. Notably, anti-pTau vaccination generates antibody responses with pharmacokinetic characteristics and target epitopes that differ substantially from the Company’s anti-Tau monoclonal antibody semorinemab, highlighting the comprehensive and complementary nature of AC Immune’s anti-Tau pipeline.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population, with very high antigen-specific titers. Importantly, it generated a much stronger antibody response compared to direct injection of exogenous antibodies. As pathological pTau is present as a precursor many years before Tau accumulation in the brain is detectable via brain imaging, such results highlight the significant promise of ACI-35.030 as an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease. We look forward to continuing to advance ACI-35.030 in our collaboration with Janssen Pharmaceuticals, Inc., as we aim to bring this potentially breakthrough vaccine to patients.”

Interim data from the Phase 1b/2a study showed:

Anti-Tau IgG response preferentially targets phosphorylated Tau in all patients;
100% of patients demonstrated an anti-pTau IgG response after the 1st injection for both lowest and second highest dosages;
Very high anti-pTau IgG titers observed following injection;
Anti-pTau IgM response was also elicited in all patients for both doses;
ACI-35.030 was safe and well tolerated with no clinically relevant safety concerns observed to date.
The companies plan to advance to the third and highest dosing group, per the study protocol.

ACI-35.030 is derived from AC Immune's proprietary SupraAntigenTM platform, which accelerates the discovery and development of conformation specific antibodies and vaccine candidates to power successful therapeutic and diagnostic approaches. Additional clinical-stage candidates derived from this platform include ACI-24, a proprietary anti-amyloid beta (Abeta) vaccine, crenezumab, an anti-Abeta monoclonal antibody, and semorinemab, an anti-Tau monoclonal antibody, which is in Phase 2 development for the treatment of moderate AD.

AC Immune’s SupraAntigenTM platform has also more recently generated conformation-specific antibodies against emerging neurodegenerative disease targets such as alpha-synuclein, TDP-43 and the NLRP3 inflammasome pathway. AC Immune’s programs directed against these emerging targets are among the most advanced and comprehensive in the field.

About the Phase 1b/2a pTau AD Vaccine Trial

AC Immune’s Phase 1b/2a pTau AD vaccine trial is a randomized, multicenter, double-blind, placebo-controlled clinical study with a primary objective to assess the safety, tolerability and immunogenicity of different doses of ACI-35.030 over a 48-week treatment phase in 32 patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.

About ACI-35.030

ACI-35.030 is a potent liposomal anti-pTau active investigational vaccine designed to elicit antibodies against phosphorylated pathological Tau protein. It is designed to reduce and facilitate the clearance of related Tau aggregates, slowing the progression of Tau-pathology and/or treating the underlying Tauopathy.

It builds on the success of AC Immune’s ACI-35 vaccine, which demonstrated an early target-specific antibody response against pTau after the first injection in the vast majority of participants in a Phase 1b study in mild-to-moderate AD. In preclinical studies, ACI-35.030 retained the excellent non-clinical safety profile and the highly specific antibody response against phosphorylated pathological Tau produced by ACI-35, while demonstrating an enhanced and more homogeneous antibody response.

AC Immune is developing the ACI-35.030 vaccine in collaboration with Janssen Pharmaceuticals, Inc., under a 2014 licensing agreement to develop and commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies.

About AC Immune SA
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

For further information, please contact:

Head of Investor Relations
Joshua Drumm, Ph.D.
AC Immune
Phone: +1 917 809 0814
Email: joshua.drumm@acimmune.com
US Media
Katie Gallagher
LaVoie Health Science
Phone: +1 617 792 3937
Email: kgallagher@lavoiehealthscience.com

European Investors & Media
Chris Maggos
LifeSci Advisors
Phone: +41 79 367 6254
Email: chris@lifesciadvisors.com
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.


Source: AC Immune SA
© 2021 GlobeNewswire, Inc.

News: $ACIU Here's Why AC Immune Jumped Higher Today

Shares of AC Immune (NASDAQ: ACIU) a re up 26% at 2:23 p.m. EDT after the biotech revealed top-line results from an early-stage clinical trial testing its Alzheimer's disease vaccine, ACI-35.030, which A C Immune is developing with Johnson & Johnson (NYSE: JNJ) . Based on the ...

Got this from ACIU - Here's Why AC Immune Jumped Higher Today

* * $ACIU Video Chart 07-16-2020 * *

Link to Video - click here to watch the technical chart video

any GREEN day is a good day

News: $ACIU 24/7 Market News- Biotech Headlines

DENVER, Colo., July 16, 2020- Today’s biotech headlines include developments from Emmaus Life Sciences, Inc. (OTCQB:EMMA), AC Immune SA (NASDAQ:ACIU), and Nabriva Therapeutics plc (NASDAQ:NBRV). Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced ...

Got this from ACIU - 24/7 Market News- Biotech Headlines

News: $ACIU AC Immune Advances phospho-Tau Alzheimer's Vaccine in Phase 1b/2a Study

Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated with the proprietary SupraAntigen ™ platform addressing proteinopathies across neurodegenerative dise...

In case you are interested ACIU - AC Immune Advances phospho-Tau Alzheimer's Vaccine in Phase 1b/2a Study

Nice trap! Weak open, vwap reclaim. Pm high to break is next target.

Will get exciting if/when they get to stage 3

Agree. Could be a short trap. They make it look weak now. Early shorts pilling in abd we coukd get a r/g move for break over P M high. Will see, all depends on volume coming in.

Nice pre market action

AC Immune Advances Phospho-Tau Alzheimer's Vaccine In Phase 1b/2a Study
7:04 am ET July 16, 2020 (Benzinga) Print
Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study

ACI-35.030 is a clinical stage vaccine generated with the proprietary SupraAntigen™ platform addressing proteinopathies across neurodegenerative diseases

LAUSANNE, Switzerland, July 16, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of the second highest dosing group in the Company's Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease (AD). The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group.

Immunization with anti-Tau vaccines has become an important strategy for the treatment of AD and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030, which is being developed in collaboration with Janssen Pharmaceuticals, Inc., is the first AD vaccine candidate designed to generate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology throughout the brain.

News: $ACIU AC Immune to Present at Jefferies 2019 London Healthcare Conference

LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London Healthcare Conference in Lo...

In case you are interested ACIU - AC Immune to Present at Jefferies 2019 London Healthcare Conference

News: $ACIU AC Immune Q3 2019 Financial Results and Business Update

 CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical...

In case you are interested ACIU - AC Immune Q3 2019 Financial Results and Business Update

volume alert, I'm loaded

What do you all use to find potential big gainers in bio tech market? Besides the catalyst site, is there something more? Thanks

You guess is as good as mine. They have nearly 9 potential products in the pipeline. It just takes 1 to hit it big with the FDA and we are off to the races.

When are we expecting holy grail PR?

The 2 day "old" news is what started the pop. Your news was like 3:30pm 2/21.

Anyways, this stock will be $9+ later this year because there was an overreaction to a failed phase 3. They have plenty going on to make the stock jump and huge pipeline.

I'm in @ $3.90. Friday was a good day to flip and re-buy but I missed it.

I don't think so. That PR was 2 days ago. Either way, we need to continue seeing positive PRs to keep the floor under the PPS until the Holy Grail PR is issued.

This is the reason for pop:

AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer's Disease
20.February 2019 13:39 CET
English
Study complements ongoing trial in the prodromal to mild population

Lausanne, Switzerland, February 20, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, is recruiting patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, known as MTAU9937A, RO7105705, in moderate Alzheimer's disease (AD). The same antibody, RG6100 (MTAU9937A, RO7105705), also is being studied by Genentech in a separate Phase 2 trial to evaluate its efficacy and safety in patients with prodromal-to-mild Alzheimer's disease. This anti-Tau monoclonal antibody was discovered and humanized as part of AC Immune's collaboration with Genentech.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: "We are highly encouraged that Genentech is broadening its clinical evaluation of our anti-Tau antibody. Interest in targeting Tau was also recently demonstrated by our newest partnership with Eli Lilly, announced in early January, to develop our small molecule Tau MorphomerTM to treat Alzheimer's. These projects illustrate AC Immune's scientific leadership in the field and are an important part of our broad portfolio of three product candidates in Phase 2 clinical testing, complementary diagnostics in clinical development, a robust early-stage pipeline and an increasingly visible focus on early projects targeting neuro-orphan and neuro-inflammation indications."

The trial, posted here, is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A, RO7105705 in an estimated 260 patients with moderate AD dementia. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. The primary endpoints are change from baseline to Week 49 in cognitive function as measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-item version (ADAS-Cog11) and change from baseline to Week 49 in functional capacities as measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL).

This anti-Tau monoclonal antibody is part of the strategic collaboration with Genentech entered into in 2012 for the research, development and commercialization of monoclonal humanized antibodies against Tau protein. RO7105705 is a humanized anti-Tau monoclonal antibody with a high specificity for pathological Tau, designed to intercept the cell-to-cell spread of pathological Tau in the extracellular space of the brain.

Tau pathology spreads with a characteristic spatiotemporal pattern throughout the brain, coinciding with both clinical symptoms and disease progression in AD. Slowing the propagation of tau pathology may therefore slow disease progression and reduce cognitive decline, and anti-tau therapies have shown promise in slowing the progression of tau pathology in animal models of tauopathy.

AC Immune has several product candidates addressing the Tau approach, including: ACI-35, an anti-pTau vaccine partnered with Janssen Pharmaceuticals, currently in a Phase 1b/2a trial, a small molecule Tau MorphomerTM, partnered with Eli Lilly and Company, that is scheduled to enter Phase 1 in 2019; and a Tau imaging agent, partnered with Life Molecular Imaging (formerly Piramal Imaging), currently in Phase 2 clinical testing.

Released today by Zacks. Any ESP (earnings surprise predictor) reading of greater than 0 implies that there is greater than a 70% probability that there will be an earnings surprise to the 'upside'. Earnings are scheduled to be released on 3/19/19. Hence the pop in PPS today!!!

Stocks to Consider (by Zacks)

Here are a few medical stocks worth considering with the right combination of elements to beat on earnings in the upcoming quarterly releases.

AC Immune SA ACIU has an Earnings ESP of +86.79% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Anyone here follow or own this stock?

ACIU~Dr. Pfeifer continued, “We remain committed to our on-going pre-clinical and clinical candidates targeting Tau and neuro-inflammation to treat Alzheimer’s disease, neuro-orphan diseases and Parkinson’s disease, which are partnered with five leading pharmaceutical partners, including Roche’s subsidiary Genentech.”

* * $ACIU Video Chart 01-30-2019 * *

Link to Video - click here to watch the technical chart video

ACIU~~4.60 -58%%%

got in at 3.47

ACIU~~4.45

buy!

ACIU~~4.34 and going,100% bounce easy coming from the bottom 3.25

ACIU~~3.75 ,-65%% ,bounce time

AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission To...

* Grant supports next step in development of potentially first alpha-synuclein PET tracer for Parkinson's disease
* Start of first-in-human study of current lead is scheduled for Q1 2019
* Follow-up grant marks longstanding collaboration with The Michael J. Fox Foundation (MJFF)

Lausanne, Switzerland, November 15, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded a follow-up grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). In 2015 AC°Immune received a research grant from the MJFF to support the development of a Parkinson's-specific diagnostic agent. Following a grant extension in 2017, the new grant is an acknowledgement of the progress AC Immune has made in this program. This grant aims to facilitate the execution of a first-in-human study for a potential alpha-synuclein PET tracer with the current lead compound. The study will commence in Q1 of 2019. The amount of the grant has not been disclosed.

Prof. Andrea Pfeifer, CEO of AC Immune, said: "We are honored to receive, for the third time, funding from the prestigious Michael J. Fox Foundation underlining our collaboration and dedication to find earlier and more accurate tools for the diagnosis of Parkinson's disease. This new follow-up grant further validates AC°Immune's leading expertise in the pathology of misfolded proteins and our vision to become a global leader in precision medicine of neurodegenerative diseases."

https://ih.advfn.com/p.php?pid=nmona&article=78695919